Palifermin (Kepivance) for myelotoxic-therapy-related mucositis.
Palifermin (Kepivance) is a recombinant keratinocyte growth factor that decreases the incidence and duration of severe oral mucositis (OM) in patients with hematologic malignancies receiving myelotoxic chemotherapy and hematopoietic stem cell support. It appears to be well tolerated and could decrease use of opioid analgesics and total parenteral nutrition in these patients.